Scholarlink

Objective <p>This study aimed to evaluate the outcomes of endovascular treatment for splenic artery aneurysms (SAAs).</p> Methods <p>A retrospective review was conducted of patients with SAAs who underwent endovascular treatment between January 2019 and June 2024. Patient demographics, aneurysm characteristics, treatment strategies, and perioperative and long-term outcomes were analyzed.</p> Results <p>A total of 19 patients with SAAs, with a median age of 53 years (IQR 47–57 years), were treated endovascularly. Of these, 15 patients were treated with embolization alone, and 4 with covered stent placement. Technical success, defined as successful deployment of devices and complete exclusion of the aneurysm on final angiography, was achieved in 18 out of 19 patients (94.74%). The mean contrast medium volume used was 88.5 ± 9.5 mL, and the median operative time was 84&#xa0;min (IQR 65–105&#xa0;min). Post-embolization syndrome (PES) occurred in 15.79% (3/19) of patients. One patient developed splenic artery dissection, and 47.37% (9/19) had splenic infarction. During a median clinical follow-up of 35.5 months (IQR 11.25–45.5 months), there was no mortality, no hepatic or intestinal ischemia, or need for reintervention in either the perioperative period or during follow-up. The median duration of CT imaging follow-up was 28 months (IQR 10.5–35.5 months). The median aneurysm diameter was 25&#xa0;mm (IQR 19.5–30.6&#xa0;mm) before treatment and decreased to 19.9&#xa0;mm (IQR 16.9–24.8&#xa0;mm) on the last follow-up CT scan (<i>P</i> = 0.130). Among the nine patients with splenic infarction, follow-up imaging revealed complete resolution of the infarcted area in four cases and a marked reduction in infarct size in the remaining five. One patient with a minor endoleak and a stable aneurysm was managed conservatively. The vast majority of aneurysms (94.74%, 18/19) were completely excluded and had achieved complete thrombosis. Univariate regression analyses found no significant association between spleen diameter and complete aneurysm thrombosis (<i>P</i> = 0.999) or the degree of aneurysm sac shrinkage (<i>P</i> = 0.297).</p> Conclusion <p>Based on our single-center experience, endovascular techniques appear to be feasible, safe, and effective for treating SAAs, with appropriate intervention tailored to anatomical location and aneurysm characteristics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Technical and clinical outcomes of endovascular treatment for splenic artery aneurysms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月20日

查看全文
  • Xiong Zhang,
  • Mo Wang,
  • Ming Li,
  • Hao He,
  • Chenzi Yang,
  • Chang Shu

摘要

Objective

This study aimed to evaluate the outcomes of endovascular treatment for splenic artery aneurysms (SAAs).

Methods

A retrospective review was conducted of patients with SAAs who underwent endovascular treatment between January 2019 and June 2024. Patient demographics, aneurysm characteristics, treatment strategies, and perioperative and long-term outcomes were analyzed.

Results

A total of 19 patients with SAAs, with a median age of 53 years (IQR 47–57 years), were treated endovascularly. Of these, 15 patients were treated with embolization alone, and 4 with covered stent placement. Technical success, defined as successful deployment of devices and complete exclusion of the aneurysm on final angiography, was achieved in 18 out of 19 patients (94.74%). The mean contrast medium volume used was 88.5 ± 9.5 mL, and the median operative time was 84 min (IQR 65–105 min). Post-embolization syndrome (PES) occurred in 15.79% (3/19) of patients. One patient developed splenic artery dissection, and 47.37% (9/19) had splenic infarction. During a median clinical follow-up of 35.5 months (IQR 11.25–45.5 months), there was no mortality, no hepatic or intestinal ischemia, or need for reintervention in either the perioperative period or during follow-up. The median duration of CT imaging follow-up was 28 months (IQR 10.5–35.5 months). The median aneurysm diameter was 25 mm (IQR 19.5–30.6 mm) before treatment and decreased to 19.9 mm (IQR 16.9–24.8 mm) on the last follow-up CT scan (P = 0.130). Among the nine patients with splenic infarction, follow-up imaging revealed complete resolution of the infarcted area in four cases and a marked reduction in infarct size in the remaining five. One patient with a minor endoleak and a stable aneurysm was managed conservatively. The vast majority of aneurysms (94.74%, 18/19) were completely excluded and had achieved complete thrombosis. Univariate regression analyses found no significant association between spleen diameter and complete aneurysm thrombosis (P = 0.999) or the degree of aneurysm sac shrinkage (P = 0.297).

Conclusion

Based on our single-center experience, endovascular techniques appear to be feasible, safe, and effective for treating SAAs, with appropriate intervention tailored to anatomical location and aneurysm characteristics.